Treatment News : Treating HIV During Pregnancy Also Lowers Risk of Transmitting Hep C to Baby - by Tim Horn

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » March 2012

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

March 16, 2012

Treating HIV During Pregnancy Also Lowers Risk of Transmitting Hep C to Baby

by Tim Horn

CROI 2012 For women living with HIV and hepatitis C virus (HCV) coinfection, using HIV antiretroviral (ARV) therapy during pregnancy may lower the risk of transmitting both viruses to their infants, according to encouraging new data presented Tuesday, March 6, at the 19th Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle.

Most research on mother-to-child transmission (MTCT) of hepatitis C was done before there was widespread access to combination ARV therapy among pregnant women living with HIV and HCV. In earlier years of the HIV pandemic, up to 19 percent of babies born to mothers living with HIV/HCV coinfection acquired HCV, versus 2 to 5 percent of babies born to mothers with HCV alone. Although combination ARV treatment has been proved to reduce MTCT of HIV, little has been known about the effects of modern-day HIV treatment combinations on MTCT of HCV.

Claudia Checa Cabot, MD, from the National Institute of Child Health and Human Development (NICHD) International Site Development Initiative (NISDI) and her international team of colleagues speculated that controlling HIV with ARV therapy in women living with HIV and hepatitis C might lower MTCT of both viruses.

Drawing from data collected from 2002 to 2008 in the Perinatal and Longitudinal Study in Latin American Countries (LILAC), Cabot and her colleagues reported that 739 of 1,409 pregnant HIV-positive women in the cohort had been tested for antibodies to HCV. Confirmatory testing for hepatitis C viral load (HCV RNA) was performed in all HCV antibody-positive women and women with a CD4 cell count of less than 200, even if the HCV antibody test result was negative.

Overall, 70 (9 percent) of the 739 women were HCV-antibody positive. Of this group, 44 (67 percent) had detectable hepatitis C virus (HCV RNA), as did an additional three women with low CD4 cell counts.

Mother-to-child transmission of HCV occurred in only four (8.5 percent) of the 47 infants born to women living with both viruses. None of the infants were born with HIV.

All of the mothers were taking ARV therapy while pregnant, and most had an HIV viral load of less than 1,000 copies when their babies were delivered.

All of the babies with hepatitis C were born to mothers with HCV RNA levels that were greater than 3.5 million copies during pregnancy. However, HCV RNA levels were not significantly lower among the mothers who did not transmit HCV to their infants.

Babies with detectable HCV RNA were considered to be living with hepatitis C. In one of the four infants, HCV RNA was less than 3,200 copies at 6 to 12 weeks after birth and became undetectable at 24 weeks.

“The HCV MTCT rate among HIV/HCV coinfected women with access to [combination ARV therapy] and well-controlled HIV infection may be lower than the transmission rates that were previously reported in other HIV/HCV coinfected populations, although our sample size and duration of study follow-up are limitations,” the researchers conclude. “Additional data from larger populations with longer infant follow-up are needed to better clarify whether populations of HIV-infected women with well-controlled HIV disease have lower HCV MTCT rates than what has been observed previously among HIV/HCV coinfected populations.”

Search: hiv, hepatitis c, hcv, transmission, mother to child, babies, infants, vertical, mtct, latin america, lilac, cabot, croi, seattle


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Hide comments

Previous Comments:


         


[Go to top]


Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    guycmh328
    Columbus
    Ohio


    usuallyhappy
    Palm Springs
    California


    Deelight4u
    BROOKLYN
    New York


    daino1972
    Columbus
    Ohio
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Are you a regular coffee drinker?
Yes
No

Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.